Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Gains from Sales and Divestitures (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Gains from Sales and Divestitures for 4 consecutive years, with $433168.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Sales and Divestitures rose 1651.52% to $433168.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $433168.0, a 1651.52% increase, with the full-year FY2024 number at $24595.0, down 74.35% from a year prior.
  • Gains from Sales and Divestitures was $433168.0 for Q3 2025 at Century Therapeutics, up from $24734.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $488758.0 in Q4 2022 to a low of $24595.0 in Q4 2024.
  • A 4-year average of $156423.3 and a median of $95877.0 in 2023 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: plummeted 80.38% in 2023, then surged 1651.52% in 2025.
  • Century Therapeutics' Gains from Sales and Divestitures stood at $488758.0 in 2022, then tumbled by 80.38% to $95877.0 in 2023, then tumbled by 74.35% to $24595.0 in 2024, then soared by 1661.2% to $433168.0 in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Gains from Sales and Divestitures are $433168.0 (Q3 2025), $24734.0 (Q2 2025), and $24734.0 (Q1 2025).